CytoSorbents Corporation Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- CytoSorbents Corporation's estimated annual revenue is currently $32.1M per year.
- CytoSorbents Corporation received $15.0M in venture funding in April 2018.
- CytoSorbents Corporation's estimated revenue per employee is $251,000
- CytoSorbents Corporation's total funding is $11.8M.
- CytoSorbents Corporation has 128 Employees.
- CytoSorbents Corporation grew their employee count by 11% last year.
- CytoSorbents Corporation currently has 1 job openings.
What Is CytoSorbents Corporation?
CytoSorbents (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend, ContrastSorb, DrugSorb and others. For more information, please visit the Company's websites: http://www.cytosorbents.com and http://www.cytosorb.comkeywords:Fitness and Wellness,Healthcare,Pharmaceuticals,Physical Security,Security